Last updated 52 days ago

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

1200 patients around the world

Available in Puerto Rico, Brazil, Argentina, Mexico

Eli Lilly and Company

45Research sites

1200Patients around the world

This study is for people with

Alzheimer disease

To 80 Years

All Gender

: Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.
Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.

: Have dementia or significant other neurological disease that can affect cognition.
Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.
Have a clinically important laboratory test result or other abnormality as determined by investigator that could be detrimental to the participant or could compromise the study.
Have any contraindications for magnetic resonance imaging (MRI).
Have a centrally read MRI demonstrating presence of ARIA-E, >4 cerebral microhemorrhages, any superficial siderosis, any macrohemorrhage, or severe white matter disease at screening.
Have had prior treatment with a passive anti-amyloid immunotherapy within <5 half-lives prior to screening.
Have received active immunization against Aβ in any other study.